Condition: Primary Immune Deficiency Disorder · Immune Deficiency Disease · Bone Marrow Failure · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase II prospective trial to assess the rates of donor engraftment using reduced intensity conditioning (RIC) hematopoietic stem cell transplant (HSCT) and post-transplant cyclophosphamide (PTCy) for patients with primary immune deficiencies (PID), immune dysregulatory syndromes (IDS), inherited bone marrow failure syndromes (IBMFS), short telomere syndromes, Fanconi anemia, and non-Fanconi DNA double-strand break (DNA-dsb) repair disorder.
This description comes directly from the study's public registry record.
Heather J Symons, MD, MHS · 4105029961 · hsymons2@jhmi.edu
Megan Petrycki, RN · 4109555068 · mpetryc1@jhmi.edu
Always discuss trial participation with your own doctor first.
| Johns Hopkins University | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04232085